Anti-SOX10 antibody [SP267],Abcam,AB227680

Anti-SOX10 antibody [SP267] (ab227680) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in Flow Cyt (Intra), ICC/IF, IHC-FoFr IHC-P and WB. Abcam's high quality manufacturing and validation processes ensure Anti-SOX10 antibody [SP267] (ab227680) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-SOX10 antibody [SP267] (ab227680) has 5 independent reviews from customers. Anti-SOX10 antibody [SP267] (ab227680) specifically detects SOX10 (UniProt ID: P56693; Molecular weight: 50kDa) and is sold in 100 µL, 500 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone SP267 - ab239752. Antibody clone SP267 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, PE, Alexa Fluor ® 555, APC, Alexa Fluor ® 594, Alexa Fluor ® 568 ( ab270150 , ab270151 , ab270152 , ab307763 , ab310845 , ab311668 , ab313897 ). Anti-SOX10 antibody [SP267] (ab227680) is a clone from the portfolio of Spring Bioscience (Roche) SP clones which have been optimised for immunohistochemistry (IHC). SOX10 is a crucial transcription factor in neuro research, particularly for its role in the development and differentiation of neural crest cells and glial cells. It is essential for the formation of Schwann cells and oligodendrocytes, which are vital for myelination in the peripheral and central nervous systems. Researchers use SOX10 to study neural crest cell fate, myelination processes and related disorders, making it vital for understanding neurodevelopmental diseases and demyelinating conditions.Additionally, SOX10 plays a significant role in melanoma, an aggressive form of skin cancer. It is highly expressed in melanoma cells and is essential for their proliferation and survival. Altered SOX10 expression can influence melanoma progression and drug resistance, making it a critical target for understanding and potentially treating melanoma. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .